pacanalotamab (AMG 420) / Amgen 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   176 News 


12»
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Phase classification, Trial termination, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  Jan 5, 2024   
    P1,  N=23, Terminated, 
    Phase classification: P1b --> P1 | Completed --> Terminated; Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420.
  • ||||||||||  Pooled Analysis on Bispecific Antibody-Related Toxicities in Multiple Myeloma (Halls G-H (San Diego Convention Center)) -  Nov 3, 2023 - Abstract #ASH2023ASH_2383;    
    Our results showed that non-BCMA bsAb were associated less hematotoxicity (combined grade 3-4 events and hypogammaglobulinemia), whereas BCMA bsAb were associated with less CRS rates. This is important information for treatment selection and mitigation strategy development aiming to optimize patient outcomes.
  • ||||||||||  elranatamab (PF-06863135) / Pfizer, AMG 211 / Amgen, pacanalotamab (AMG 420) / Amgen
    Journal, IO biomarker:  Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma. (Pubmed Central) -  Jul 31, 2022   
    The final model simulations indicated that the number of immune synapses is similar (~55/tumor cell) between two distinct clinical stage B cell maturation antigen (BCMA)-targeting TCEs, PF-06863135 in an IgG format and AMG420 in a BiTE format, at their respective efficacious doses in multiple myeloma patients. This result demonstrates the applicability of the developed computational modeling framework to molecular design optimization and clinical benchmarking for TCEs, thus suggesting that this framework can be applied to other targets to provide a quantitative means to facilitate model-informed best-in-class TCE discovery and development.
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Trial completion, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  May 17, 2022   
    P1b,  N=23, Completed, 
    This result demonstrates the applicability of the developed computational modeling framework to molecular design optimization and clinical benchmarking for TCEs, thus suggesting that this framework can be applied to other targets to provide a quantitative means to facilitate model-informed best-in-class TCE discovery and development. Active, not recruiting --> Completed
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Trial completion date, Trial primary completion date, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  Sep 23, 2021   
    P1b,  N=23, Active, not recruiting, 
    Phase II / III studies are being conducted to evaluate this potential treatment approach in patients with MM. Trial completion date: Feb 2025 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Journal:  Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. (Pubmed Central) -  Dec 18, 2020   
    These agents encompass monoclonal antibodies, such as the drug conjugate belantamab mafodotin; bispecific T-cell engager strategies exemplified by AMG 420; and chimeric antigen receptor (CAR) T-cell therapeutics that include idecabtagene vicleucel (bb2121) and JNJ-68284528. In this study of AMG 420 in patients with relapsed/refractory multiple myeloma, the response rate was 70%, including 50% MRD-negative complete responses, at 400 μg/d, the MTD for this study.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal, IO Biomarker:  T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. (Pubmed Central) -  Nov 25, 2020   
    Cytokine release syndrome is the most common adverse event, which can be adequately managed with tocilizumab or steroids...GPRC5D, CD38 and FcRH5), are also evaluated in early phase clinical trials. Such bispecific antibodies, targeting other antigens, may be given to patients with low baseline BCMA expression, disease with substantial heterogeneity in BCMA expression, following prior BCMA-targeted therapy, or combined with BCMA bispecific antibodies to prevent development of antigen escape.
  • ||||||||||  AMG 420 / Amgen
    [VIRTUAL] Outcome of BCMA Bite (AMG420) Therapy in Relapse and Refractory Multiple Myeloma (RRMM) Patients (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_4021;    
    P1
    Despite this small numbers and reporting of single institutional experience these results are encouraging in light of recent long term data of BCMA CAR-T therapy reporting on a PFS of less than 12 months. The data warrante further investigation of -BCMA targeted BiAB’s as a treatment modality in RRMM patients.
  • ||||||||||  AMG 420 / Amgen
    [VIRTUAL] Local Activator and T Cell Engager (αBCMA x αPD-L1 x αCD3) with Enhanced Tumor Killing and Minimal Cytokine Release for the Treatment of Multiple Myeloma (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2733;    
    The most advanced of these is AMG 420, which showed significantly improved response rates in relapsed/refractory multiple myeloma (MM) patients...Collectively, these findings demonstrate that the simultaneous T cell redirection and tumor-specific checkpoint inhibition with the LocATE leads to an improved therapeutic index with robust tumor cell killing and low levels of cytokine release. Capable of counteracting adaptive immune resistance caused by increased PD-1/PD-L1 signaling, the LocATE antibody has the prospect to significantly improve survival for multiple myeloma patients.
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Phase classification, Trial primary completion date, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  Aug 17, 2020   
    P1b,  N=23, Active, not recruiting, 
    Importantly, clinical results to date suggest that these therapies may hold promise for deep and durable responses and support further investigation in earlier lines of treatment, including newly diagnosed MM. Phase classification: P1b/2 --> P1b | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  AMG 420 / Amgen, Blenrep (belantamab mafodotin) / GSK
    Journal:  Myeloma: next generation immunotherapy. (Pubmed Central) -  Jun 11, 2020   
    These agents have unique toxicities that require close monitoring, but they are moving forward in larger registration studies and in combination with standard MM agents. Additional ADCs and bispecific antibodies targeting BCMA and other surface antigens (eg, CD38, CD46, CD48, FcRH5, and G protein-coupled receptor, class C group 5 member D) are moving forward in phase 1 trials and may provide even more options for MM patients.
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  May 7, 2020   
    P1b/2,  N=23, Active, not recruiting, 
    Additional ADCs and bispecific antibodies targeting BCMA and other surface antigens (eg, CD38, CD46, CD48, FcRH5, and G protein-coupled receptor, class C group 5 member D) are moving forward in phase 1 trials and may provide even more options for MM patients. Recruiting --> Active, not recruiting | N=15 --> 23 | Trial completion date: Oct 2025 --> Feb 2025 | Trial primary completion date: Nov 2021 --> Feb 2021
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Trial completion date, Trial primary completion date, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  Aug 29, 2019   
    P1b/2,  N=120, Recruiting, 
    Trial completion date: Nov 2020 --> Oct 2025 | Trial primary completion date: Nov 2020 --> Nov 2021 Trial completion date: Apr 2025 --> Nov 2020 | Trial primary completion date: Jan 2025 --> Nov 2020
  • ||||||||||  pacanalotamab (AMG 420) / Amgen
    Trial primary completion date, Monotherapy:  Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) -  Aug 11, 2019   
    P1b/2,  N=120, Recruiting, 
    Trial completion date: Apr 2025 --> Nov 2020 | Trial primary completion date: Jan 2025 --> Nov 2020 Trial primary completion date: Oct 2021 --> Jan 2025